Added to YB: 2024-02-13
Pitch date: 2024-02-11
IBRX [bullish]
ImmunityBio, Inc.
+85.16%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Market Cap
$5.9B
Pitch Price
$4.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-28.56
P/E
-14.31
EV/Sales
78.25
Sector
Biotechnology
Category
special_situation
Show full summary:
ImmunityBio: Buy Low Now Vs. Buy High Later
$IBRX: Anktiva PDUFA 4/23 for bladder cancer; prior CRL was mfg issue not drug; superior to $MRK Keytruda; 32% short interest on low float; major ex-US partner post-approval; trials: lung/pancreatic cancer+vaccines; risks: FDA, trials, dilution; high risk/reward
Read full article (7 min)